Catalog No.S1615 Synonyms: R-64766

For research use only.

Risperidone (R-64766) is a mutil-targeted antagonist for dopamine, serotonin, adrenergic and histamine receptors, used to treat schizophrenia and bipolar disorder.

Risperidone  Chemical Structure

CAS No. 106266-06-2

Selleck's Risperidone has been cited by 3 Publications

Purity & Quality Control

Choose Selective 5-HT Receptor Inhibitors

Other 5-HT Receptor Products

Biological Activity

Description Risperidone (R-64766) is a mutil-targeted antagonist for dopamine, serotonin, adrenergic and histamine receptors, used to treat schizophrenia and bipolar disorder.
5-HT2A [7] α2c-adrenergic receptor [7] D2 receptor [7] D3 receptor [7] D2L Receptor [7] Click to View More Targets
0.17 nM(Ki) 1.3 nM(Ki) 3.57 nM(Ki) 3.6 nM(Ki) 4.16 nM(Ki)
In vitro

Risperidone binds to both DA and serotonin (5HT) receptors, particularly in the neurons of striatal and limbic structures. Risperidone significantly affects brain nerve growth factor (NGF) level suggesting that it influences the turnover of endogenous growth factors. Risperidone significantly decreases BDNF concentrations in frontal cortex, occipital cortex and hippocampus and decreases or increases TrkB receptors in selected brain structures. [1] Risperidone significantly increases D(2) binding in medial prefrontal cortex by 34% in rat forebrain regions. Risperidone produces even greater up-regulation of D(4) receptors in CPu (37%), NAc (32%), and HIP (37%) in rat forebrain regions. [2] Risperidone significantly inhibits the production of NO and proinflammatory cytokines by activated microglia. [3] Risperidone (1-50 mM) significantly enhances the intracellular accumulation of Rh123 in Caco-2 cells by inhibiting P-gp activity with an IC(50) value of 5.87 mM. [4]

In vivo

Risperidone does not significantly affect bodyweight gain (BWG), food intake(FI), glucose tolerance or leptin levels, even though prolactin and corticosterone are significantly elevated in male rats. Risperidone significantly increases BWG and FI in female rats. [5] Risperidone (0.05 mg/kg) increases food intake and leptin gene expression in white adipose tissue (WAT), but the rate of bodyweight gain is not affected in rats. Risperidone (0.5 mg/kg) causes a reduction in bodyweight gain, as well as enhanced Ucp1 gene expression in BAT and serum prolactin concentrations in rats.[6]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 410.48


CAS No. 106266-06-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04567524 Recruiting Drug: LYN-005 Schizophrenia Schizoaffective Lyndra Inc.|Worldwide Clinical Trials August 13 2020 Phase 2
NCT03978832 Completed Drug: PERSERIS|Drug: Risperidone Schizophrenia Indivior Inc. June 28 2019 Phase 4
NCT03503318 Completed Drug: TV-46000|Drug: Placebo Schizophrenia Teva Branded Pharmaceutical Products R&D Inc. April 27 2018 Phase 3
NCT03302364 Unknown status Drug: Risperidone Schizophrenia|Mental Illness Cui Yimin|Peking University First Hospital October 22 2017 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Risperidone | Risperidone ic50 | Risperidone price | Risperidone cost | Risperidone solubility dmso | Risperidone purchase | Risperidone manufacturer | Risperidone research buy | Risperidone order | Risperidone mouse | Risperidone chemical structure | Risperidone mw | Risperidone molecular weight | Risperidone datasheet | Risperidone supplier | Risperidone in vitro | Risperidone cell line | Risperidone concentration | Risperidone nmr